Challenges and opportunities of adding CFTR modulators for cystic fibrosis to the WHO essential medicines list [0.03%]
囊性纤维化跨膜传导调节剂增列至世卫组织基本药物标准清单的挑战与机遇
Enrico Costa,Hendrika A van den Ham,Hubert G M Leufkens
Enrico Costa
Pulmonary endpoints in clinical trials for children with cystic fibrosis under two years of age [0.03%]
两岁以下囊性纤维化儿童临床试验的肺功能终点指标分析
Tim Lee,Kate Hill,Daan Caudri et al.
Tim Lee et al.
Cystic fibrosis is a lifelong progressive disease in which lung disease is the main prognostic factor, where starting early treatment is crucial for improving long-term outcomes. Therefore, new treatment should be available as early as poss...
Elexacaftor/tezacaftor/ivacaftor prescription in lung transplant recipients with cystic fibrosis in the US [0.03%]
美国肺移植受者囊性纤维化患者中沙库巴曲/-tezacaftor/_ivacaftor的处方情况
Nora C Burdis,Miranda C Bradford,Sonya L Heltshe et al.
Nora C Burdis et al.
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) has dramatically improved pulmonary and extrapulmonary manifestations of cystic fibrosis (CF). ETI clinical trials excluded lung transplant (LTx) recipients and current p...
Monitoring early antibiotic treatment with anti-Pseudomonas aeruginosa serology: a comparison of two specific antibody panels [0.03%]
抗假单胞菌抗体检测监测早期抗生素治疗的疗效：两种特异性抗体谱系的比较研究
Daniela Dolce,Silvia Campana,Cristina Fevola et al.
Daniela Dolce et al.
Background: Pseudomonas aeruginosa chronic infection can cause lung function decline in people with cystic fibrosis, and early antibiotic treatment (EAT) is crucial to prevent it. While culture methods are standard for mo...
Pregnancy and neonatal outcome following in utero exposure to CFTR modulators: A multicentre prospective case series [0.03%]
产前暴露于囊性纤维化跨膜传导调节剂对母体妊娠结局和新生儿的影响：一项多中心前瞻性病例系列研究
Sophie Gautier,Bénédicte Coulm,Marie-Andrée Thompson-Bos et al.
Sophie Gautier et al.
Background: Clinical data regarding in utero exposure to CFTR modulators (CFTRm) are limited. Our objective was to describe pregnancy outcomes, with particular attention to malformations, and neonatal adverse outcomes amo...
Tobacco smoke exposure is associated with diminished longitudinal benefit of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis [0.03%]
烟草烟雾暴露与囊性纤维化患者使用艾沙卡福塔/-te扎卡福塔-/伊伐卡福塔治疗的纵向益处降低有关
William T Harris,Elizabeth H Baker,Jennifer S Guimbellot et al.
William T Harris et al.
Background: Tobacco smoke exposure (TSE) is associated with diminished benefit of ivacaftor and tezacaftor/ivacaftor in people with CF (PwCF). This study assessed the association of TSE with clinical benefit from elexacaf...
A standard operating procedure for reducing risk from medications prohibited during clinical trials in cystic fibrosis [0.03%]
囊性纤维化临床试验中禁止使用药物的安全操作规程
M Le Sayec,G Davies,M D Waller et al.
M Le Sayec et al.
Fecal microbiota changes in people with cystic fibrosis after 6 months of elexacaftor/tezacaftor/ivacaftor: Findings from the promise study [0.03%]
囊性纤维化患者使用elexacaftor/tezacaftor/ivacaftor治疗6个月后的粪便微生物群变化：来自Promise研究的结果
Jennifer T Duong,Hillary S Hayden,Adrian J Verster et al.
Jennifer T Duong et al.
Background: People with cystic fibrosis (PwCF) often have fecal dysbioses relative to those without CF, characterized by increased pro-inflammatory microbiota and gastrointestinal (GI) inflammation as measured by fecal ca...
Evolution of hepatobiliary involvement in cystic fibrosis children on CFTR modulators [0.03%]
囊性纤维化转运调节剂对囊性纤维化儿童肝胆影响的演变
Mélanie Auvray,Nolwenn Laborde,Marie Mittaine et al.
Mélanie Auvray et al.
Background: There are great changes in cystic fibrosis (CF) disease following introduction of modulator treatments. We aimed to focus on the evolution of hepatobiliary involvement following lumacaftor-ivacaftor (LI) and e...
Air travel and cystic fibrosis: An algorithm to assess the risk of In-Flight Hypoxemia [0.03%]
空中旅行与囊性纤维化：评估机上低氧血症风险的处理方案
A Akerø,E Edvardsen,P L Finstad et al.
A Akerø et al.
Background: Air travel may cause significant hypoxemia in patients with cystic fibrosis (CF). A pre-flight algorithm has previously been validated for patients with chronic obstructive pulmonary disease (COPD). No such to...